Drug Profile
PRCN 323
Alternative Names: ABCD1 gene therapy - Neuralgene; PRCN-323Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Neuralgene
- Class Adrenoleucodystrophy gene therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Adrenoleucodystrophy
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for clinical-Phase-Unknown development in Adrenoleucodystrophy in Mexico (Intrathecal, Injection)
- 07 Sep 2020 Clinical development is ongoing for Adrenoleucodystrophy in Mexico (Intrathecal) (Neuralgene pipeline, September 2020)
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Adrenoleucodystrophy in Mexico (Intrathecal, Injection)